BioCentury | Aug 11, 2014
Strategy

Profusion of exclusions

...SIX:ROG; OTCQX:RHHBY) Blood glucose test ü Apidra insulin glulisine Sanofi (Euronext:SAN; NYSE:SNY) Diabetes ü Duexis ibuprofen/famotidine...
...Johnson & Johnson (NYSE:JNJ) ü Drug classes added to 2015 exclusion list Anti-Inflammatory/anti-ulcer agents Duexis ibuprofen/famotidine...
BioCentury | Aug 4, 2014
Finance

Highlights of weekly biotech stock moves

...Corp. (NYSE:CVS) and Express Scripts Holding Co. (NASDAQ:ESRX) notified the company that arthritis drugs Duexis ibuprofen/famotidine...
...will be placed on their exclusion lists effective Jan. 1. Horizon said about 20-30% of Duexis...
...The company reported 1Q14 U.S. Vimovo sales of $34 million and $13.9 million in U.S. Duexis...
BioCentury | Aug 4, 2014
Clinical News

Duexis ibuprofen/famotidine regulatory update

...see BioCentury, Nov. 25, 2013). Horizon Pharma Inc. (NASDAQ:HZNP), Deerfield, Ill. Product: Duexis ibuprofen/famotidine ( HZT-501...
...Scripts Holding Co. (NASDAQ:ESRX, St. Louis, Mo.) notified the company that arthritis drugs Duexis ibuprofen/famotidine (HZT-501...
...sales of $34 million for Vimovo and $13.9 million for Duexis, estimates about 20-30% of Duexis...
BioCentury | Jul 29, 2014
Company News

Horizon falls on Duexis, Vimovo coverage concerns

...and Express Scripts Holding Co. (NASDAQ:ESRX) notified the company that arthritis drugs Duexis ibuprofen/famotidine ( HZT-501...
...sales of $34 million for Vimovo and $13.9 million for Duexis, estimates about 20-30% of Duexis...
...wholesale price (AWP) of Vimovo increased 597% on Jan. 1, 2014, and the AWP of Duexis...
BioCentury | Mar 24, 2014
Company News

Horizon Pharma, Vidara Therapeutics deal

...of Actimmune of $58.9 million. Horizon markets four drugs, including autoimmune drugs Duexis ibuprofen/famotidine ( HZT-501...
BioCentury | Mar 20, 2014
Top Story

Horizon Pharma to acquire Vidara

...of Actimmune of $58.9 million. Horizon markets four drugs, including autoimmune drugs Duexis ibuprofen/famotidine ( HZT-501...
BioCentury | Feb 3, 2014
Finance

Highlights of weekly biotech stock moves

...November from AstraZeneca plc (LSE:AZN; NYSE:AZN). Horizon's marketed products include autoimmune drugs Duexis ibuprofen/famotidine ( HZT-501...
BioCentury | Nov 25, 2013
Analyst Picks & Changes

Analyst picks & changes

...risk of developing NSAID-associated gastric ulcers. Nash believes delayed-release Vimovo will complement Horizon's fast-acting Duexis ibuprofen/famotidine...
BioCentury | Mar 18, 2013
Clinical News

Duexis ibuprofen/famotidine regulatory update

...Horizon said the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved Duexis ibuprofen/famotidine to treat...
...plans to seek 1 or more commercialization partners for Duexis in Europe. The MAA for Duexis...
...see BioCentury, June 25, 2012). Horizon Pharma Inc. (NASDAQ:HZNP), Deerfield, Ill. Product: Duexis ibuprofen/famotidine ( HZT-501...
BioCentury | Jan 7, 2013
Clinical News

Duexis ibuprofen/famotidine regulatory update

...Horizon said the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) recommended approval of Duexis ibuprofen/famotidine...
...ankylosing spondylitis and to reduce the risk of developing upper gastrointestinal ulcers. The MAA for Duexis...
...see BioCentury, June 25, 2012). Horizon Pharma Inc. (NASDAQ:HZNP), Deerfield, Ill. Product: Duexis ibuprofen/famotidine ( HZT-501...
Items per page:
1 - 10 of 44